Study on the effectiveness and safety of fecal bacteria transplantation for cognitive impairment

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200065110

Enrollment

Unknown

Registered

2022-10-28

Start date

2022-10-31

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive impairment

Interventions

Conventional treatment group:Administration of donepezil

Fecal bacteria transplantation treatment group:Fecal transplantation is given on top of conventional treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 60 patients with cognitive impairment aged 18 years<=age<=80 years old; 2. The diagnosis of cognitive impairment is based on the standards of the Fifth Edition Revised DSMV-R of the Diagnostic and Statistical Manual for Mental Disorders. A written informed consent form signed and dated at least 3 months after the diagnosis of cognitive impairment.

Exclusion criteria

Exclusion criteria: 1. Suffering from short bowel syndrome and gastroesophageal reflux; 2. Recurrent aspiration; 3. Significantly decreased immunity (immunosuppressive drugs, recent chemotherapy, decompensated liver disease due to cirrhosis, advanced human immunodeficiency virus [HIV]/AIDS [CD4 count<250] cells)/ µ L] , neutrophil (absolute neutrophil count<1000/ µ L) Recent bone marrow transplantation or other causes of severe immune deficiency; 4. Those who do not agree to sign the patient's informed consent; 5. Take probiotics within 1 month.

Design outcomes

Primary

Measure	Time frame
ADAS-Cog;MoCA scores;	—

Countries

china

Contacts

Public ContactLiuzhou

Affiliated Hospital of Guangdong Medical Universit

5285805@qq.com+86 13543558835

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026